Management of melanoma

被引:63
作者
Corrie, Pippa [1 ]
Hategan, Mirela [1 ]
Fife, Kate [1 ]
Parkinson, Christine [1 ]
机构
[1] Addenbrookes Hosp, Cambridge Univ Hosp NHS Fdn Trust, Cambridge Canc Ctr, Cambridge CB2 0QQ, England
关键词
melanoma; primary melanoma; advanced melanoma; metastatic melanoma; epidemiology; prevention; screening; diagnosis; treatment; MUTATED METASTATIC MELANOMA; SENTINEL-NODE BIOPSY; HIGH-RISK MELANOMA; OPEN-LABEL; IMPROVED SURVIVAL; ADJUVANT THERAPY; MEK INHIBITION; PHASE-II; BRAF; MULTICENTER;
D O I
10.1093/bmb/ldu019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Melanoma is a potentially curable cancer, but around 20% of patients will develop disease which is beyond surgical clearance. Rising incidence alongside breakthroughs in understanding the molecular biology of this disease identifying systemic therapies offering survival gains now demand amore proactive, integrated approach to melanoma management. Sources of data: PubMed references relating to aspects of melanoma research and treatment. Areas of agreement: Rapidly rising incidence throughout the world. Effective surgery as well as new molecular targeted systemic biological agents and immunotherapies necessitating early diagnosis and multidisciplinary therapeutic interventions. Areas of controversy: Role of screening and prevention. Benefit of interventions for locoregional melanoma, including role of sentinel lymph node biopsy. Integration and sequencing of treatments for unresectable melanoma. Growing points: Molecular determinants of melanoma influencing disease outcome and treatment decisions. Areas timely for developing research: Education and training of patient and healthcare professionals. Role of screening, surveillance and follow-up strategies. Biology of melanoma guiding treatment decisions.
引用
收藏
页码:149 / 162
页数:14
相关论文
共 54 条
[1]   PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma [J].
Abe, Azusa ;
Minaguchi, Takeo ;
Ochi, Hiroyuki ;
Onuki, Mamiko ;
Okada, Satoshi ;
Matsumoto, Koji ;
Satoh, Toyomi ;
Oki, Akinori ;
Yoshikawa, Hiroyuki .
HUMAN PATHOLOGY, 2013, 44 (02) :199-207
[2]   BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance [J].
Alcala, Alexander Marzuka ;
Flaherty, Keith T. .
CLINICAL CANCER RESEARCH, 2012, 18 (01) :33-39
[3]  
[Anonymous], 2013, POSITION PAP FOLLOW
[4]   MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study [J].
Ascierto, Paolo A. ;
Schadendorf, Dirk ;
Berking, Carola ;
Agarwala, Sanjiv S. ;
van Herpen, Carla M. L. ;
Queirolo, Paola ;
Blank, Christian U. ;
Hauschild, Axel ;
Beck, J. Thaddeus ;
St-Pierre, Annie ;
Niazi, Faiz ;
Wandel, Simon ;
Peters, Malte ;
Zubel, Angela ;
Dummer, Reinhard .
LANCET ONCOLOGY, 2013, 14 (03) :249-256
[5]   Final Version of 2009 AJCC Melanoma Staging and Classification [J].
Balch, Charles M. ;
Gershenwald, Jeffrey E. ;
Soong, Seng-jaw ;
Thompson, John F. ;
Atkins, Michael B. ;
Byrd, David R. ;
Buzaid, Antonio C. ;
Cochran, Alistair J. ;
Coit, Daniel G. ;
Ding, Shouluan ;
Eggermont, Alexander M. ;
Flaherty, Keith T. ;
Gimotty, Phyllis A. ;
Kirkwood, John M. ;
McMasters, Kelly M. ;
Mihm, Martin C., Jr. ;
Morton, Donald L. ;
Ross, Merrick I. ;
Sober, Arthur J. ;
Sondak, Vernon K. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206
[6]   Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis [J].
Boniol, Mathieu ;
Autier, Philippe ;
Boyle, Peter ;
Gandini, Sara .
BMJ-BRITISH MEDICAL JOURNAL, 2012, 345
[7]   Tumor Homogeneity between Primary and Metastatic Sites for BRAF Status in Metastatic Melanoma Determined by Immunohistochemical and Molecular Testing [J].
Boursault, Lucile ;
Haddad, Veronique ;
Vergier, Beatrice ;
Cappellen, David ;
Verdon, Severine ;
Bellocq, Jean-Pierre ;
Jouary, Thomas ;
Merlio, Jean-Philippe .
PLOS ONE, 2013, 8 (08)
[8]   Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial [J].
Burmeister, Bryan H. ;
Henderson, Michael A. ;
Ainslie, Jill ;
Fisher, Richard ;
Di Iulio, Juliana ;
Smithers, B. Mark ;
Hong, Angela ;
Shannon, Kerwin ;
Scolyer, Richard A. ;
Carruthers, Scott ;
Coventry, Brendon J. ;
Babington, Scott ;
Duprat, Joao ;
Hoekstra, Harald J. ;
Thompson, John F. .
LANCET ONCOLOGY, 2012, 13 (06) :589-597
[9]  
Cancer Research UK, MEL INC STAT
[10]   Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].
Chapman, Paul B. ;
Hauschild, Axel ;
Robert, Caroline ;
Haanen, John B. ;
Ascierto, Paolo ;
Larkin, James ;
Dummer, Reinhard ;
Garbe, Claus ;
Testori, Alessandro ;
Maio, Michele ;
Hogg, David ;
Lorigan, Paul ;
Lebbe, Celeste ;
Jouary, Thomas ;
Schadendorf, Dirk ;
Ribas, Antoni ;
O'Day, Steven J. ;
Sosman, Jeffrey A. ;
Kirkwood, John M. ;
Eggermont, Alexander M. M. ;
Dreno, Brigitte ;
Nolop, Keith ;
Li, Jiang ;
Nelson, Betty ;
Hou, Jeannie ;
Lee, Richard J. ;
Flaherty, Keith T. ;
McArthur, Grant A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516